ATLANTA – Forty years after the establishment of ABVD – adriamycin, bleomycin, vinblastine and dacarbazine – as standard-of-care front-line therapy in patients with previously untreated advanced classical Hodgkin lymphoma (cHL), Seattle Genetics Inc. (Seagen) revealed details supporting its contention that replacing bleomycin with Adcetris (brentuximab vedotin) could improve efficacy and reduce toxicity in those patients, improving their chance of a cure with the first round of treatment.